Employees: 696
Size Eiken Chemical (4549.T) is a Japan Health Care company (Medical Specialties) with a market value of $466M, the 1108th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,273 on 18 Nov 2026.
Performance Over six months the shares fell 20.1%, against -15.2% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 3.9% over the last twelve months (peer median +1.9%); the operating margin is 6.5% (peer median 2.7%).
Valuation It trades at 24.5× forward earnings against a peer median of 21.1× (4th most expensive of 9).
Capital Return on invested capital runs 1.6 points below its cost of capital (6.8% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥42.9B | ¥41.9B | ¥40.5B | ¥40.1B | ¥43.3B |
| Revenue growth | — | +3% | +1% | -7% | — |
| Gross profit | ¥15.9B | ¥16.2B | ¥16.5B | ¥16.7B | ¥20.5B |
| EBITDA | ¥5.39B | ¥5.46B | ¥5.55B | ¥5.71B | ¥9.58B |
| Net income | ¥1.85B | ¥3.71B | ¥2.23B | ¥2.63B | ¥5.74B |
| Free cash flow | n/a | -¥1.81B | ¥812M | ¥1.77B | ¥4.35B |
| Capital expenditure | n/a | ¥5.86B | ¥5.38B | ¥2.15B | ¥3.29B |
| Total debt | ¥5.80B | ¥7.29B | ¥4.47B | ¥4.33B | ¥4.31B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4549.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.6% | -4.7% | 6th lowest of 21 |
| 6-month return | -20.1% | -15.2% | 9th lowest of 21 |
| Distance from 52-week high | -35.1% | -41.7% | 9th highest of 21 |
| Revenue growth (TTM) | +3.9% | +1.9% | 10th highest of 20 |
| Operating margin | 6.5% | 2.7% | 8th highest of 20 |
| Forward P/E | 24.5× | 21.1× | 4th most expensive of 9 |
| ROIC minus cost of capital | -1.6 pp | -2.2 pp | 8th highest of 18 |
| EV / EBITDA | 12.5× | n/a | — |
| Net debt / EBITDA | -1.3× | -0.8× | 2nd least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Eiken Chemical 4549.T | Japan | $466M | -20% | +4% | 6% | 24.5× | n/a | n/a |
| MiMedx MDXG | United States | $464M | -16% | -23% | -8% | n/a | 10.9% | +11.0% |
| WELL LEAD MEDICAL 603309.SS | China | $473M | -22% | +1% | 15% | 11.9× | -5.9% | +7.7% |
| Beijing Leadman Biochemistry 300289.SZ | China | $460M | -9% | +46% | 1% | n/a | 36.0% | -6.9% |
| PROTEINA 468530.KS | South Korea | $460M | +5% | -59% | -1,178% | n/a | n/a | n/a |
| AngioDynamics ANGO | United States | $476M | -4% | +8% | -6% | n/a | n/a | n/a |
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 23% | 32.6× | 7.1% | +10.0% |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -8% | n/a | 55.3% | -4.7% |
| Guangdong Shirongzhaoye 002016.SZ | China | $453M | -26% | -31% | 3% | n/a | 21.5% | -11.7% |
| Shanghai Kindly Enterprises Development 603987.SS | China | $452M | -12% | 0% | 10% | n/a | -1.0% | -2.8% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 31% | 22.4× | 4.3% | +24.4% |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 13% | 6.9× | -6.5% | -4.3% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -51% | n/a | n/a | n/a |
| Clarity Pharmaceuticals CU6.AX | Australia | $444M | -33% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 3% | 25.8× | n/a | n/a |
| medmix MEDX.SW | Switzerland | $494M | +11% | -7% | 6% | 19.4× | 4.5% | +5.0% |
| Huaren Pharmaceutical 300110.SZ | China | $440M | -16% | -3% | 6% | n/a | 5.8% | +0.3% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $436M | +39% | +5% | 11% | 35.7× | 20.6% | +2.2% |
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 24% | 19.7× | 20.1% | +4.2% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $500M | -27% | +18% | -60% | n/a | n/a | n/a |
| Mobia Medical MOBI | United States | $434M | +2% | +105% | -145% | n/a | n/a | n/a |